What Has Been the Growth of the Vivotif Market So Far?
The vivotif market has seen considerable growth due to a variety of factors.
• In recent times, the vivotif market size has expanded by XX (HCAGR). Projecting growth from $XX million in 2024 to $XX million in 2025, the market is set to increase at a compound annual growth rate (CAGR) of XX%.
The historical period of growth can be credited to factors such as increased international travel, a rise in occurrences of typhoid fever, growing urbanization, enhanced healthcare availability, and increasing disposable income.
How Will the Vivotif Market?
The vivotif market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for Vivotif is anticipated to expand at XX (FCAGR) in the forthcoming years, reaching a value of $XX million by 2029 with a CAGR of XX%.
Several factors can account for this growth during the forecast period, such as rising knowledge about the advantages of immunization, escalating occurrences of typhoid fever, the convenience and efficiency of oral vaccines, progression in vaccine technology, and amplified research activities. Some major trends will be observed during the forecast, including growing inclination towards oral vaccines, intensified attention on travel vaccines, including Vivotif in travel health kits, emergence of combination vaccines, and transition towards preventive healthcare.
Which Factors Are Boosting Growth In The Vivotif Market?
The growth of the Vivotif market is anticipated to be propelled by the rising cases of typhoid fever. This bacterial infection is caused by Salmonella Typhi and is transmitted through polluted food or water, leading to fever, fatigue, and abdominal discomfort. Lack of sanitary facilities, access to clean water, and increasing antibiotic resistance are contributing to the surge in typhoid fever cases, especially in poorer regions. Vivotif provides a preventative oral vaccine against Salmonella Typhi, helping to decrease the prevalence of typhoid fever in areas with poor sanitation. For instance, GOV.UK, a government platform based in the UK, reported in August 2024 that there were about 645 cases of typhoid fever in England, Wales, and Northern Ireland in 2023, a rise from 470 cases in 2022. This underscores the year-over-year increase in disease prevalence. Consequently, the surge in typhoid fever cases is fuelling the growth of the Vivotif market.
What Key Areas Define The Segmentation Of The Global Vivotif Market?
The vivotif market covered in this report is segmented –
1) By Clinical Indication: Typhoid, Other Indications
2) By Distribution Channel: Direct Sales, Online Pharmacies, Retail Pharmacies
3) By End-User: Adults, Pediatric
Pre-Book The Vivotif Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Who Are the Key Players In The Vivotif Market?
Major companies operating in the vivotif market are:
• Bavarian Nordic A/S
What Is The Most Dominant Region In The Vivotif Market?
Asia-Pacific was the largest region in the vivotif market in 2024. The regions covered in the vivotif market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
